Central Nervous System Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling
Mid-Phase III
TNX-102 SL Posttraumatic Stress Disorder (PTSD)
Phase II start — targeting 2Q 2023
Phase II
TNX-102 SL Long COVID
Phase II start — PREVAIL study enrolling
Phase II
TNX-601 ER Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids
Phase II start — targeting 1Q 2023
Phase I
TNX-1300 Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation
Mid-Phase II
TNX-1900 Chronic Migraine
Phase II start — targeting 1Q 2023
Phase II
Infectious Disease Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-1850 COVID-19 Vaccine
Preclinical
Preclinical
TNX-801 Smallpox and Monkeypox Preventing Vaccine
Phase I start — targeting 2H 2023
Preclinical
TNX-3600 COVID-19 Therapeutic/Preventative Platform (fully human monoclonal antibodies)
Preclinical
Preclinical
TNX-3800 COVID-19 Therapeutic/Preventative (humanized monoclonal antibodies)
Preclinical
Preclinical
Rare Disease Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-2900 Prader-Willi Syndrome
Preclinical – FDA Orphan Drug Designation
Preclinical